A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors

Inclusion Criteria: * Primary tissue from patient's surgery must be epidermal growth factor receptor (EGFR)-positive by certain tests * Patients may have up to 4 cycles of chemotherapy after surgery * Complete removal of the tumor by surgery * Able to start drug under the following timelines: * 6 months from the day of surgery for patients who get chemotherapy * 3 months from the day of surgery for those who do not get chemotherapy * Confirmed diagnosis of Stage IB-IIIA NSCLC * Patients must be accessible for follow-up visits Exclusion Criteria: * History of prior radiotherapy for NSCLC either before or after surgery * History of heart disease or uncontrolled heart arrhythmias within the previous year * History of poorly controlled gastrointestinal (GI) disorders that could affect the absorption of study drug * History of other cancer except certain skin or cervical cancers, patients who have had other cancer are eligible if they have remained disease free for at least 5 years * Patients who have received chemotherapy for NSCLC before surgery * Tumors with mixed histology of NSCLC and Small Cell Lung Cancer (SCLC). Patients with carcinoid tumors are not eligible.